Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | C1S | P09871 | 1/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.39 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 2/20 | 0.38 |
| ▸ | LPO | P22079 | 1/20 | 0.38 |
| ▸ | NMT1 | P30419 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | MMP1 | P03956 | 3/20 | 0.34 |
| ▸ | MMP2 | P08253 | 3/20 | 0.34 |
| ▸ | MMP9 | P14780 | 3/20 | 0.34 |
| ▸ | MMP8 | P22894 | 3/20 | 0.34 |
| ▸ | MMP13 | P45452 | 3/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24051973 | 0.82 | MCL1 (0.46) | MCL1C1SPIK3C3KAT5KAT8 | |
| SCHEMBL24051971 | 0.79 | MCL1 (0.44) | MCL1C1SPIK3C3KAT5KAT8 | |
| SCHEMBL24051974 | 0.78 | MCL1 (0.43) | MCL1C1SPIK3C3KAT5KAT8 | |
| SCHEMBL25751558 | 0.78 | MCL1 (0.46) | MCL1C1SPIK3C3KAT5KAT8 | |
| SCHEMBL9033147 | 0.78 | LPO (0.41) | MCL1C1SPIK3C3KAT5KAT8 | |
| Hydrochloric Acid SCHEMBL28316626 | 0.76 | LPO (0.40) | MCL1C1SPIK3C3KAT5KAT8 | |
| SCHEMBL569909 | 0.75 | LPO (0.43) | MCL1C1SPIK3C3KAT5KAT8 | |
| SCHEMBL604082 | 0.74 | LPO (0.41) | MCL1C1SPIK3C3KAT5KAT8 | |
| SCHEMBL5610390 | 0.74 | LPO (0.41) | MCL1C1SPIK3C3KAT5KAT8 | |
| SCHEMBL5610393 | 0.74 | LPO (0.41) | MCL1C1SPIK3C3FDPSLPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210053915-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2021-02-25 | — | — | US | disclosed |
| US-10829445-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190144380-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2019-05-16 | — | — | US | disclosed |
| US-10179765-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-9969684-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170305847-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2017-10-26 | — | — | US | disclosed |
| US-9725410-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-08-08 | — | — | US | disclosed |
| EP-3124471-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | The Johns Hopkins University (US) | 2017-02-01 | — | — | EP | disclosed |
| US-20170022154-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2017-01-26 | — | — | US | disclosed |
| EP-2504003-B1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS INC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20140336396-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2014-11-13 | — | — | US | disclosed |
| EP-2489350-A1 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | Johns Hopkins University School of Medicine (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20110306614-A1 | N-Hydroxylsulfonamide Derivatives as New Physiologically Useful Nitroxyl Donors | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-12-15 | — | — | US | disclosed |
| US-8030356-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030356-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20110160200-A1 | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2011063339-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| US-20070299107-A1 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | NATIONAL SCIENCE FOUNDATION | 2007-12-27 | — | — | US | disclosed |
| US-20070299107-A1 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | NATIONAL SCIENCE FOUNDATION | 2007-12-27 | — | — | US | disclosed |
| WO-2007109175-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306614-A1 | N-Hydroxylsulfonamide Derivatives as New Physiologically Useful Nitroxyl Donors | TNNI3, TNNC1, NME4 | MCL1 2568/4885C1S 4718/4885PIK3C3 4884/4885 |
| US-20210053915-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | TNNI3, TNNC1, TNNT2 | MCL1 2665/4885C1S 4727/4885PIK3C3 4883/4885 |
| US-10829445-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | TNNI3, TNNC1, TNNT2 | MCL1 2665/4885C1S 4727/4885PIK3C3 4883/4885 |
| US-20110160200-A1 | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension | NOS2, NOS3, NOS1 | MCL1 963/4885C1S 4801/4885PIK3C3 3945/4885 |
| US-20190144380-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | TNNI3, TNNC1, TNNT2 | MCL1 2665/4885C1S 4727/4885PIK3C3 4883/4885 |
| US-20070299107-A1 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | TNNI3, TNNC1, NME4 | MCL1 2568/4885C1S 4718/4885PIK3C3 4884/4885 |
| US-20170022154-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | TNNI3, TNNC1, NME4 | MCL1 2568/4885C1S 4718/4885PIK3C3 4884/4885 |
| US-10179765-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | TNNI3, TNNC1, TNNT2 | MCL1 2665/4885C1S 4727/4885PIK3C3 4883/4885 |
| US-20140336396-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | TNNI3, TNNC1, NME4 | MCL1 2568/4885C1S 4718/4885PIK3C3 4884/4885 |
| US-20170305847-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | TNNI3, TNNC1, NME4 | MCL1 2568/4885C1S 4718/4885PIK3C3 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.